Literature DB >> 25919184

Costs of vaccine programs across 94 low- and middle-income countries.

Allison Portnoy1, Sachiko Ozawa2, Simrun Grewal3, Bryan A Norman4, Jayant Rajgopal5, Katrin M Gorham6, Leila A Haidari7, Shawn T Brown8, Bruce Y Lee9.   

Abstract

While new mechanisms such as advance market commitments and co-financing policies of the GAVI Alliance are allowing low- and middle-income countries to gain access to vaccines faster than ever, understanding the full scope of vaccine program costs is essential to ensure adequate resource mobilization. This costing analysis examines the vaccine costs, supply chain costs, and service delivery costs of immunization programs for routine immunization and for supplemental immunization activities (SIAs) for vaccines related to 18 antigens in 94 countries across the decade, 2011-2020. Vaccine costs were calculated using GAVI price forecasts for GAVI-eligible countries, and assumptions from the PAHO Revolving Fund and UNICEF for middle-income countries not supported by the GAVI Alliance. Vaccine introductions and coverage levels were projected primarily based on GAVI's Adjusted Demand Forecast. Supply chain costs including costs of transportation, storage, and labor were estimated by developing a mechanistic model using data generated by the HERMES discrete event simulation models. Service delivery costs were abstracted from comprehensive multi-year plans for the majority of GAVI-eligible countries and regression analysis was conducted to extrapolate costs to additional countries. The analysis shows that the delivery of the full vaccination program across 94 countries would cost a total of $62 billion (95% uncertainty range: $43-$87 billion) over the decade, including $51 billion ($34-$73 billion) for routine immunization and $11 billion ($7-$17 billion) for SIAs. More than half of these costs stem from service delivery at $34 billion ($21-$51 billion)-with an additional $24 billion ($13-$41 billion) in vaccine costs and $4 billion ($3-$5 billion) in supply chain costs. The findings present the global costs to attain the goals envisioned during the Decade of Vaccines to prevent millions of deaths by 2020 through more equitable access to existing vaccines for people in all communities. By projecting the full costs of immunization programs, our findings may aid to garner greater country and donor commitments toward adequate resource mobilization and efficient allocation. As service delivery costs have increasingly become the main driver of vaccination program costs, it is essential to pay additional consideration to health systems strengthening.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Costs; Routine immunization; Supplemental immunization activities; Supply chain; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 25919184     DOI: 10.1016/j.vaccine.2014.12.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  A systems map of the economic considerations for vaccination: Application to hard-to-reach populations.

Authors:  Sarah N Cox; Patrick T Wedlock; Sarah W Pallas; Elizabeth A Mitgang; Tatenda T Yemeke; Sarah M Bartsch; Taiwo Abimbola; Sheryl S Sigemund; Aaron Wallace; Sachiko Ozawa; Bruce Y Lee
Journal:  Vaccine       Date:  2021-05-25       Impact factor: 3.641

2.  Current costs & projected financial needs of India's Universal Immunization Programme.

Authors:  Susmita Chatterjee; Manish Pant; Pradeep Haldar; Mahesh Kumar Aggarwal; Ramanan Laxminarayan
Journal:  Indian J Med Res       Date:  2016-06       Impact factor: 2.375

3.  Funding gap for immunization across 94 low- and middle-income countries.

Authors:  Sachiko Ozawa; Simrun Grewal; Allison Portnoy; Anushua Sinha; Richard Arilotta; Meghan L Stack; Logan Brenzel
Journal:  Vaccine       Date:  2016-10-28       Impact factor: 3.641

4.  Demographics, epidemiology and the impact of vaccination campaigns in a measles-free world - Can elimination be maintained?

Authors:  J M Prada; C J E Metcalf; S Takahashi; J Lessler; A J Tatem; M Ferrari
Journal:  Vaccine       Date:  2017-02-16       Impact factor: 3.641

5.  Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study.

Authors:  Carlos Riumallo-Herl; Angela Y Chang; Samantha Clark; Dagna Constenla; Andrew Clark; Logan Brenzel; Stéphane Verguet
Journal:  BMJ Glob Health       Date:  2018-04-09

6.  Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.

Authors:  Simon de Montigny; Blythe J S Adamson; Benoît R Mâsse; Louis P Garrison; James G Kublin; Peter B Gilbert; Dobromir T Dimitrov
Journal:  Sci Rep       Date:  2018-04-17       Impact factor: 4.379

7.  Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries.

Authors:  Karin Stenberg; Odd Hanssen; Tessa Tan-Torres Edejer; Melanie Bertram; Callum Brindley; Andreia Meshreky; James E Rosen; John Stover; Paul Verboom; Rachel Sanders; Agnès Soucat
Journal:  Lancet Glob Health       Date:  2017-07-17       Impact factor: 26.763

8.  Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001-2020.

Authors:  Sachiko Ozawa; Samantha Clark; Allison Portnoy; Simrun Grewal; Meghan L Stack; Anushua Sinha; Andrew Mirelman; Heather Franklin; Ingrid K Friberg; Yvonne Tam; Neff Walker; Andrew Clark; Matthew Ferrari; Chutima Suraratdecha; Steven Sweet; Sue J Goldie; Tini Garske; Michelle Li; Peter M Hansen; Hope L Johnson; Damian Walker
Journal:  Bull World Health Organ       Date:  2017-06-27       Impact factor: 9.408

9.  The cost structure of routine infant immunization services: a systematic analysis of six countries.

Authors:  Fangli Geng; Christian Suharlim; Logan Brenzel; Stephen C Resch; Nicolas A Menzies
Journal:  Health Policy Plan       Date:  2017-10-01       Impact factor: 3.344

10.  Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration.

Authors:  Klodeta Kura; Benjamin S Collyer; Jaspreet Toor; James E Truscott; T Deirdre Hollingsworth; Matt J Keeling; Roy M Anderson
Journal:  Vaccine       Date:  2020-05-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.